Disclosures: Carlos Alventosa-Mateu: Nothing to Disclose, Mara Dolores Ocete Mochn: Nothing to Disclose, Juan Catal Bauset: Nothing to Disclose, Javier Hernndez Felices: Nothing to Disclose, Juan Jos Urquijo Ponce: Nothing to Disclose, Mercedes Latorre Snchez: Nothing to Disclose, Inmaculada Castell Miralles: Nothing to Disclose, Concepcin Cardona Gimeno: Nothing to Disclose, Moiss Diago: Nothing to Disclose 564 ASSOCIATIONS BETWEEN BIOMARKERS AND MAGNETIC RESONANCE IMAGING-DERIVED ANALI SCORE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: ANALYSIS FROM THE PHASE 3 PRIMIS STUDY Michael Trauner 1 Jun Xu 2 Xiangyu Liu 3 Kaiyi Zhu 3 Xiaomin Lu 3 Sharlene Lim 3 William Barchuk 3 Lisa Boyette 3 Clare Tempany 4 Zachary Goodman 5 Atsushi Tanaka 6 Douglas Thorburn 7 Cynthia Levy 8 Christopher Bowlus 9 , 1 Medical University of Vienna, 2 Gilead Sciences, Inc., 3 Gilead Sciences Inc., 4 Brigham and Women's Hospital, Harvard University, 5 INOVA Fairfax Hospital, 6 Teikyo University School of Medicine, 7 Royal Free Hospital, 8 University of Miami, 9 University of California, Davis Background and Aim: Magnetic resonance cholangiopancreatography (MRCP) is the standard diagnostic method for patients with primary sclerosing cholangitis (PSC)
When formulated for skincare, these peptides act as delivery systems
Vanholder, R
Brand 1 was a precisely quantified tablet manufactured from an aqueous solution of iodine and KI
pH, temperature, and substrate are among the processing parameters in the allergenicity reduction is microbial strain utilized in fermentation
